With the increasing use of antifibrotic therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in non-IPF interstitial lung diseases (ILDs), radiological evaluation has become essential for diagnosis, treatment planning, and monitoring disease progression [1]. Although pulmonary function tests (PFTs) guide treatment decisions and assess disease progression, their reliability is limited by variability related to patient or technician factors [2,3]. Therefore, r…